Titel
Safety and Efficacy of Continuous Subcutaneous Foslevodopa-
Foscarbidopa in Patients with Advanced Parkinson’s Disease:
a Randomised, Double-blind, Active-Controlled, Phase 3 Trial
Referenz
Michael J Soileau et al.,
Lancet Neurol 2022; 21: 1099-109
Fachrichtungen
Indikationen
Fortgeschrittener Parkinson
Parkinson
Wirkstoffe
Foscarbidopa
Foslevodopa